Psoriatic arthritis
Paul Studenic Stiddyo
4 years 4 months ago
#OP0224 Estimating clinical meaningful threshold for disease activity and improvement in composite measures of disease activity in 139 PsA patients over 3 clinical visits. Usefulness for clinics and further testing in different settings warranted
@RheumNow #EULAR2021 https://t.co/mwHJwIhRVE
Paul Studenic Stiddyo
4 years 4 months ago
#OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results
PE: ACR20 51% active vs 26% on PLC
PASI90: 55% active vs. 10% PLC
#EULAR2021 @RheumNow https://t.co/UkZLcXTNnq
Paul Studenic Stiddyo
4 years 4 months ago
Several domains of disease in #PsA need to be considered. Composite scores have the benefit of providing a summary.
What is your favourite composite score for PsA in your clinical practice?
#EULAR2021 @RheumNow
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com
Listen by Clicking below:
1. EULAR2021 - Day2a
2. EULAR2021 - Day2b
Dr. Rachel Tate uptoTate
4 years 4 months ago
The COSMOS study results showed that GUS 100 mg Q8W showed ⬆️ ACR20 vs PBO at W24 in TNFi IR PsA pts who had tried 1-2 prior TNFi. What MOA do you choose after 1st TNFi IR in your PsA pts? Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/Jb7GqkHtYz
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients with PsA” Dr.
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 4 months ago
⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN pathways ⭐️Recent studies (POETYK PSO-1/2) show that it outperforms Otezla per PASI75 ⭐️OP0227 shows it is also efficacious for active PsA vs PBO w/ no serious AEs #EULAR2021 @Rheumnow https://t.co/qA1NsLzQsF
Dr. John Cush RheumNow
4 years 4 months ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow and its faculty.
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Here are some of my highlights from Day 2.
Dr. John Cush RheumNow
4 years 4 months ago
Fecal Transplantation as Potential PsA Treatment: Dr. Eric Dein ( @ejdein1) #EULAR2021
https://t.co/ItYAEIJZSW https://t.co/uHnY9cWLEj
Dr. Rachel Tate uptoTate
4 years 4 months ago
"What we really need in SpA/PsA is personalized medicine in order to choose the best drug MOA for our patients." Dr. Laura Coates addressing paradox of choice in treatment options. I remain hopeful for better biomarkers for future precision medicine approach. #EULAR2021 @RheumNow https://t.co/nIDksfTe7h
Dr. John Cush RheumNow
4 years 4 months ago
Q-DAPSA for Measuring Disease Activity in PsA by Dr. Rachel Tate ( @uptoTate) #EULAR2021
https://t.co/fbi3Kbd2GS https://t.co/afRnle1EJK
Aurelie Najm AurelieRheumo
4 years 4 months ago
DISCOVER 1&2: whole blood transcriptome in PsA: dysregulation of immune cell profiles vs. Ctrl
Guselkumab modulates genes expr towards normalization of immune cell composition. Would be interesting to look at STissue
signatures too 🧐 @StefanSiebert1 #POS0195 @Rheumnow #EULAR2021 https://t.co/7WChCP3U6W
Poster Hall